Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
about
Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy.Assessing the quality of prescribing and monitoring erythropoiesis-stimulating agents in the nursing home setting.Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan databaseStaff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practicesImprovement in appropriate utilization of recombinant human erythropoietin pre- and post-implementation of a required order form.
P2860
Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use and prescribing patterns f ...... outpatient hospital settings.
@en
Use and prescribing patterns f ...... outpatient hospital settings.
@nl
type
label
Use and prescribing patterns f ...... outpatient hospital settings.
@en
Use and prescribing patterns f ...... outpatient hospital settings.
@nl
prefLabel
Use and prescribing patterns f ...... outpatient hospital settings.
@en
Use and prescribing patterns f ...... outpatient hospital settings.
@nl
P2093
P356
P1476
Use and prescribing patterns f ...... outpatient hospital settings.
@en
P2093
Donald F Brophy
James Jorgenson
Jerry Siegel
Paul Audhya
Philip E Johnson
Thomas Comstock
P304
P356
10.2146/AJHP070526
P577
2008-09-01T00:00:00Z